Business Description
Middle East Pharmaceutical Industries Co
ISIN : SA160G51UO10
Total Employee Number:
731Compare
Compare
Traded in other countries / regions
4016.Saudi IPO Date
2024-02-27Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 0.61 | |||||
Interest Coverage | 24.09 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 8.52 | |||||
Beneish M-Score | -2.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.89 | |||||
9-Day RSI | 39.21 | |||||
14-Day RSI | 44.36 | |||||
3-1 Month Momentum % | 0.09 | |||||
6-1 Month Momentum % | -2.6 | |||||
12-1 Month Momentum % | -9.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.85 | |||||
Quick Ratio | 2.18 | |||||
Cash Ratio | 0.13 | |||||
Days Inventory | 198.01 | |||||
Days Sales Outstanding | 182.52 | |||||
Days Payable | 90.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.29 | |||||
Dividend Payout Ratio | 0.7 | |||||
Forward Dividend Yield % | 2.29 | |||||
5-Year Yield-on-Cost % | 2.29 | |||||
Shareholder Yield % | 2.23 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.28 | |||||
Operating Margin % | 23.92 | |||||
Net Margin % | 21.19 | |||||
EBITDA Margin % | 27.87 | |||||
FCF Margin % | 6.8 | |||||
OCF Margin % | 15.54 | |||||
ROE % | 26.42 | |||||
ROA % | 18.01 | |||||
ROIC % | 21.99 | |||||
ROC (Joel Greenblatt) % | 28.76 | |||||
ROCE % | 26.49 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.11 | |||||
Forward PE Ratio | 11.28 | |||||
PE Ratio without NRI | 20.11 | |||||
PS Ratio | 4.26 | |||||
PB Ratio | 5.03 | |||||
Price-to-Tangible-Book | 5.93 | |||||
Price-to-Free-Cash-Flow | 62.63 | |||||
Price-to-Operating-Cash-Flow | 27.39 | |||||
EV-to-EBIT | 18.66 | |||||
EV-to-EBITDA | 15.86 | |||||
EV-to-Revenue | 4.42 | |||||
EV-to-FCF | 64.99 | |||||
Price-to-Graham-Number | 2.3 | |||||
| Price-to-Net-Current-Asset-Value | 9.55 | |||||
Earnings Yield (Greenblatt) % | 5.36 | |||||
FCF Yield % | 1.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Middle East Pharmaceutical Industries Co Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ï·¼) | 493.251 | ||
| EPS (TTM) (ï·¼) | 2.983 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 21.35 | ||
| 14-Day RSI | 44.36 | ||
| 14-Day ATR (ï·¼) | 1.329963 | ||
| 20-Day SMA (ï·¼) | 61.045 | ||
| 12-1 Month Momentum % | -9.21 | ||
| 52-Week Range (ï·¼) | 53.885714 - 79.085714 | ||
| Shares Outstanding (Mil) | 35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Middle East Pharmaceutical Industries Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Middle East Pharmaceutical Industries Co Stock Events
| Event | Date | Price (ï·¼) | ||
|---|---|---|---|---|
| 1.75:1 Stock Split | 2026-05-12 | 58.86 (-1.90%) | ||
| SAR 0.754286 Cash Dividend | 2026-03-30 | 56.14 (-0.25%) | ||
| SAR 0.628571 Cash Dividend | 2025-09-02 | 72.74 (+1.84%) | ||
| SAR 0.714286 Cash Dividend | 2025-05-04 | 75.54 (-0.15%) | ||
| SAR 0.428571 Cash Dividend | 2024-09-02 | 77.49 (+0.00%) |
Show
Entries
Middle East Pharmaceutical Industries Co Frequently Asked Questions
What is Middle East Pharmaceutical Industries Co(SAU:4016)'s stock price today?
The current price of SAU:4016 is ï·¼60.00. The 52 week high of SAU:4016 is ï·¼79.09 and 52 week low is ï·¼53.89.
When is next earnings date of Middle East Pharmaceutical Industries Co(SAU:4016)?
The next earnings date of Middle East Pharmaceutical Industries Co(SAU:4016) is .
Does Middle East Pharmaceutical Industries Co(SAU:4016) pay dividends? If so, how much?
The Dividend Yield %  of Middle East Pharmaceutical Industries Co(SAU:4016) is 2.29% (As of Today), Highest Dividend Payout Ratio of Middle East Pharmaceutical Industries Co(SAU:4016) was 0.7. The lowest was 0.19. And the median was 0.34. The  Forward Dividend Yield % of Middle East Pharmaceutical Industries Co(SAU:4016) is 2.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Middle East Pharmaceutical Industries Co
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers